Table 3 Characteristics of the 20 interviewees
From: Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?
Patient | Gender M/F | Duration of HIV diagnosis | CDC | ART | ART regimen |
|---|---|---|---|---|---|
1 | F | 17 | A | RAL/LPV | BID |
2 | M | 23 | A | TDF/FTC/DRV/r | OD |
3 | M | 18 | C | TDF/FTC/EFV | OD |
4 | M | 32 | A | TDF/FTC/RAL | BID |
5 | M | 9 | C | TDF/FTC/EFV | OD |
6 | M | 6 | A | TDF/FTC/RPV | OD |
7 | F | 35 | A | TDF/FTC/RAL | OD |
8 | M | 32 | C | TDF/FTC/DRV/r | OD |
9 | M | 25 | A | TDF/FTC | OD |
10 | M | 33 | A | ABC/3TC/EFV | OD |
11 | M | 14 | A | TDF/FTC/ETR | OD |
12 | M | 7 | A | TDF/FTC/RPV | OD |
13 | F | 33 | A | TDF/FTC/DRV/r | OD |
14 | F | 18 | C | TDF/FTC/LPV/r | BID |
15 | M | 34 | B | ABC/3TC/EFV | OD |
16 | M | 32 | A | TDF/FTC/DRV/r | BID |
17 | M | 33 | C | TDF/FTC/DRV/r | BID |
18 | F | 22 | A | ABC/3TC/ETV | OD |
19 | F | 9 | A | DRV/r | OD |
20 | F | 7 | A | TDF/FTC/EFV | OD |